Review article: The pharmacodynamics and pharmacokinetics of proton pump inhibitors - Overview and clinical implications

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 20, Issue 6, 2004, Pages 1-10

  Robinson, M ^a,b  

^a UNIVERSITY OF OKLAHOMA   (United States)

^b Oklahoma Foundation for Digestive Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; ANTIBIOTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; DIAZEPAM; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE;

ANTIBIOTIC THERAPY; CHRONICITY; CLINICAL TRIAL; DISEASE CONTROL; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DUODENUM ULCER; ERADICATION THERAPY; ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; HEALING; HEALTH CARE COST; HEARTBURN; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; META ANALYSIS; PATHOGENESIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; REVIEW; STOMACH ACID; STOMACH ACID SECRETION; STOMACH DISEASE; STOMACH PH; STOMACH ULCER; SYMPTOM;

EID: 9944249092     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.02160.x     Document Type: Review

References (68)

1. Farley A, Wruble L, Humphries TJ. Rabeprazole vs. ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Am J Gastroenterol 2000; 95: 1894-9.
2. Huang JQ, Hunt RH. pH. healing rate and symptom relief in acid-related diseases. Yale J Biol Med 1996; 69: 159-74.
3. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798-810.
4. Gerson LB, Robbins AS, Garber A, Hornberger J, Triadafilopoulos G. A cost-effectiveness analysis of prescribing strategics in the management of gastroesophageal reflux disease. Am J Gastroenterol 2000; 95: 395-407.
5. Ofman JJ, Yamashita BD, Siddique RM, Larson LR, Willian MK. Cost effectiveness of rabeprazole versus generic ranitidine for symptom resolution in patients with erosive esophagitis. Am J Manag Care 2000; 6: 905-16.
6. Miner P Jr, Orr W, Filippone J, Jokubaitis L, Sloan S. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol 2002; 97: 1332-9.
7. Robinson M, Fitzgerald S, Hegedus R, Murthy A, Jokubaitis L. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis. Aliment Pharmacol Ther 2002; 16: 445-54.
8. Sloan S. Rabeprazole provides better heartburn relief compared to omeprazole in the first 3 and 7 days of treatment. Gut 2000; 47(Suppl. 3): A62(Abstract).
9. Sanders SW. Pathogenesis and treatment of acid peptic disorders: comparison of proton pump inhibitors with other antiulcer agents. Clin Ther 1996; 18: 2-34.
10. Richardson P, Hawkey CJ, Stack WA. Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders. Drugs 1998; 56: 307-35.
11. Sachs G, Shin JM, Briving C, Wallmark B, Hersey S. The pharmacology of the gastric acid pump: the H+,K+ ATPase. Annu Rev Pharmacol Toxicol 1995; 35: 277-305.
12. Howden CW. Optimizing the pharmacology of acid control in acid-related disorders. Am J Gastroenterol 1997; 92(4 Suppl.): 17S-21S.
13. Lambert R. Review article: current practice and future perspectives in the management of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1997; 11: 651-62.
14. Bell NJ, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastrooesophageal reflux disease. Digestion 1992; 51(Suppl. 1): 59-67.
15. Hunt RH. Importance of pH control in the management of GERD. Arch Intern Med 1999; 159: 649-57.
16. Kahrilas PJ. Gastroesophageal reflux disease. JAMA 1996; 276: 983-8.
17. Sandvik AK, Brenna E, Waldum HL. Review article: the pharmacological inhibition of gastric acid secretion - tolerance and rebound. Aliment Pharmacol Ther 1997; 11: 1013-8.
18. Earnest DL, Robinson M. Treatment advances in acid secretory disorders: the promise of rapid symptom relief with disease resolution. Am J Gastroenterol 1999; 94(11 Suppl.): S17-24.
19. Colin-Jones DG. The role and limitations of H2-receptor antagonists in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995; 9(Suppl. 1): 9-14.
20. Hurlimann S, Abbuhl B, Inauen W, Halter F. Comparison of acid inhibition by either oral high-dose ranitidine or omeprazole. Aliment Pharmacol Ther 1994; 8: 193-201.
21. Lachman L, Howden CW. Twenty-four-hour intragastric pH: tolerance within 5 days of continuous ranitidine administration. Am J Gastroenterol 2000; 95: 57-61.
22. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1999; 94: 1434-42.
23. Jones R, Bytzer P. Review article: acid suppression in the management of gastro-oesophageal reflux disease - an appraisal of treatment options in primary care. Aliment Pharmacol Ther 2001; 15: 765-72.
24. Robinson M, Sahba B, Avner D, Jhala N, Greski-Rose PA, Jennings DE. A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. The Multicentre Investigation Group. Aliment Pharmacol Ther 1995; 9: 25-31.
25. Fitzgerald RC, Lascar R, Triadafilopoulos G. Review article: Barrett's oesophagus, dysplasia and pharmacologic acid suppression. Aliment Pharmacol Ther 2001; 15: 269-76.
26. Sachs G, Shin JM, Munson K, et al. Review article: the control of gastric acid and Helicobacter pylori eradication. Aliment Pharmacol Ther 2000; 14: 1383-401.
27. Burget DW, Chiverton SG, Hunt RH. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology 1990; 99: 345-51.
28. Sachs G. Proton pump inhibitors and acid-related diseases. Pharmacotherapy 1997; 17: 22-37.
29. Eriksson S, Langstrom G, Rikner L, Carlsson R, Naesdal J. Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis. Eur J Gastroenterol Hepatol 1995; 7: 467-75.
30. Morgan DG, Burget DW, Howden CW, et al. Rates of duodenal ulcer (DU) healing by drug classes: a meta-analysis. Gastroenterology 1993; 104: A150(Abstract).
31. Breiter JR, Riff D, Humphries TJ. Rabeprazole is superior to ranitidine in the management of active duodenal ulcer disease: results of a double-blind, randomized North American study. Am J Gastroenterol 2000; 95: 936-42.
32. Poynard T, Lemaire M, Agostini H. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. Eur J Gastroenterol Hepatol 1995; 7: 661-5.
33. Fitton A, Wiseman L. Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs 1996; 51: 460-82.
34. Hunt RH, Cederberg C, Dent J, et al. Optimizing acid suppression for treatment of acid-related diseases. Dig Dis Sci 1995; 40(Suppl. 2): 24S-49S.
35. Prakash A, Faulds D. Rabeprazole. Drugs 1998; 55: 261-7.
36. Tunis SR, Sheinhait IA, Schmid CH, Bishop DJ, Ross SD. Lansoprazole compared with histamine2-receptor antagonists in healing gastric ulcers: a meta-analysis. Clin Ther 1997; 19: 743-57.
37. Bonagura AF, Dabezies MA. Helicobacter pylori infection. The importance of eradication in patients with gastric disease. Postgrad Med 1996; 100: 115-6,19-20,23-4.
38. National Institute of Health. Helicobacter pylori in peptic ulcer disease. NIH Concensus Statement 7-9 February 1994; 12: 1-22.
39. Welage LS, Berardi RR. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc (Wash) 2000; 40: 52-62.
40. Klotz U. Pharmacokinetic considerations in the eradication of Helicobacter pylori. Clin Pharmacokinet 2000; 38: 243-70.
41. Joelsson B, Johnsson F. Heartburn - the acid test. Gut 1989; 30: 1523-5.
42. Huang JQ, Hunt RH. pH, healing rate, and symptom relief in patients with GERD. Yale J Biol Med 1999; 72: 181-94.
43. Hunt RH. The relationship between the control of pH and healing and symptom relief in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995; 9(Suppl. 1): 3-7.
44. Williams MP, Pounder RE. Review article: the pharmacology of rabeprazole. Aliment Pharmacol Ther 1999: 13(Suppl. 3): 3-10.
45. Sachs G, Humphries TJ. Rabeprazole: pharmacology, pharmacokinetics, and potential for drug interactions. Aliment Pharmacol Ther 1999; 13(Suppl. 3): 1-2.
46. Swan SK, Hoyumpa AM, Merritt GJ. Review article: the pharmacokinetics of rabeprazole in health and disease. Aliment Pharmacol Ther 1999; 13(Suppl. 3): 11-7.
47. Thomson AB. Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole and rabeprazole. Curr Gastroenterol Rep 2000; 2: 482-93.
48. Kromer W, Horbach S, Luhmann R. Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis. Pharmacology 1999; 59: 57-77.
49. Vanderhoff BT, Tahboub RM. Proton pump inhibitors: an update. Am Fam Physician 2002; 66: 273-80.
50. Besancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J Biol Chem 1997; 272: 22438-46.
51. Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther 2003; 17: 1507-14.
52. Gardner JD, Sloan S, Barth JA. Rabeprazole vs. omeprazole: onset, duration, and magnitude of gastric antisecretory effects. Gut 2000; 47: 43(Abstract).
53. Stedman CA, Barclay ML. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000; 14: 963-78.
54. Röhss K, Wilder-Smith C, Claar-Nilsson C, Hasselgren G. Esomeprazole 40 mg provides more effective acid control than standard doses of all other proton-pump inhibitors. Gastroenterology 2001; 120(Suppl. 1): 2 (Abstract).
55. Miner P Jr, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole. and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003; 98: 2616-20.
56. Furuta T, Ohashi K, Kamata T, et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998; 129: 1027-30.
57. Tanigawara Y, Aoyama N, Kita T, et al, CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. Clin Pharmacol Ther 1999; 66: 528-34.
58. Spencer CM, Faulds D. Esomeprazole. Drugs 2000; 60: 321-31.
59. Andersson T, Röhss K, Bredberg E, Hassan-Alin M. Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. Aliment Pharmacol Ther 2001; 15: 1563-9.
60. Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs 2003; 63: 2739-54.
61. Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors - emphasis on rabeprazole. Aliment Pharmacol Ther 1999; 13(Suppl. 3): 27-36.
62. Kendall MJ. Review article: esomeprazole - the first proton pump inhibitor to be developed as an isomer. Aliment Pharmacol Ther 2003; 17(Suppl. 1): 1-4.
63. Lindberg P, Keeling D, Fryklund J, Andersson T, Lundborg P, Carlsson E. Review article: esomeprazole - enhanced bioavailability, specificity for the proton pump and inhibition of acid secretion. Aliment Pharmacol Ther 2003; 17: 481-8.
64. Andersson T, Cederberg C, Edvardsson G, Heggelund A. Lundborg P. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin Pharmacol Ther 1990; 47: 79-85.
65. Caraco Y, Tateishi T, Wood AJ. Interethnic difference in omeprazole's inhibition of diazepam metabolism. Clin Pharmacol Ther 1995; 58: 62-72.
66. Humphries TJ, Merritt GJ. Review article: drug interactions with agents used to treat acid-related diseases. Aliment Pharmacol Ther 1999; 13(Suppl. 3): 18-26.
67. Langtry HD, Markham A. Rabeprazole: a review of its use in acid-related gastrointestinal disorders. Drugs 1999; 58: 725-42.
68. Ishizaki T, Chiba K, Manabe K, et al. Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation. Clin Pharmacol Ther 1995; 58: 155-64.